Índice
Literatura académica sobre el tema "Analyse radiomique"
Crea una cita precisa en los estilos APA, MLA, Chicago, Harvard y otros
Consulte las listas temáticas de artículos, libros, tesis, actas de conferencias y otras fuentes académicas sobre el tema "Analyse radiomique".
Junto a cada fuente en la lista de referencias hay un botón "Agregar a la bibliografía". Pulsa este botón, y generaremos automáticamente la referencia bibliográfica para la obra elegida en el estilo de cita que necesites: APA, MLA, Harvard, Vancouver, Chicago, etc.
También puede descargar el texto completo de la publicación académica en formato pdf y leer en línea su resumen siempre que esté disponible en los metadatos.
Artículos de revistas sobre el tema "Analyse radiomique"
Flory, Violaine, Lydiane Mondot, Fanny Burel-Vandenbos, Eve Denis, Stéphane Chanalet, Fabien Almairac, Véronique Bourg et al. "Analyse radiomique des gliomes de bas grades : une étude rétrospective". Journal of Neuroradiology 47, n.º 2 (marzo de 2020): 82–83. http://dx.doi.org/10.1016/j.neurad.2019.12.006.
Texto completoBourbonne, V., R. Da-Ano, F. Lucia, G. Dissaux, J. Bert, O. Pradier, D. Visvikis, M. Hatt y U. Schick. "Analyse radiomique de la distribution dosimétrique tridimensionnelle pour la prédiction de la toxicité liée à la radiothérapie du cancer pulmonaire". Cancer/Radiothérapie 24, n.º 6-7 (octubre de 2020): 781–82. http://dx.doi.org/10.1016/j.canrad.2020.08.025.
Texto completoLucia, F., V. Bourbonne, D. Visvikis, O. Miranda, G. Dissaux, O. Pradier, F. Tixier et al. "Analyse radiomique de la distribution dosimétrique tridimensionnelle pour la prédiction de la toxicité liée à la radiothérapie du cancer du col de l’utérus". Cancer/Radiothérapie 24, n.º 6-7 (octubre de 2020): 782. http://dx.doi.org/10.1016/j.canrad.2020.08.026.
Texto completoBros, M., T. Zaragori, F. Rech, M. Blonski, L. Tallandier y A. Verger. "Étude de l’effet de la prémédication par Carbidopa en TEP à la 18F-FDOPA pour les tumeurs cérébrales : une analyse statique, dynamique et radiomique". Médecine Nucléaire 45, n.º 4 (julio de 2021): 176. http://dx.doi.org/10.1016/j.mednuc.2021.06.010.
Texto completoBordron, A., V. Bourbonne, E. Rio, B. Badic, O. Miranda, O. Pradier, M. Hatt, D. Visvikis, F. Lucia y U. Schick. "Prédiction de la réponse pathologique complète à la chimioradiothérapie néoadjuvante à l’aide d’une analyse radiomique basée sur l’imagerie par résonance magnétique pour le cancer du rectum localement évolué". Cancer/Radiothérapie 25, n.º 6-7 (octubre de 2021): 741–42. http://dx.doi.org/10.1016/j.canrad.2021.07.030.
Texto completoGiraud, N., A. Huchet, C. Pouypoudat, M. Bacci, S. Bringer, C. Herran, F. Ortiz et al. "Peut-on deviner le type histologique du cancer primitif en regardant la métastase cérébrale ? Analyse radiomique par IRM et machine-learning appliqués aux cancers primitifs bronchiques et mélanomateux". Cancer/Radiothérapie 23, n.º 6-7 (octubre de 2019): 837. http://dx.doi.org/10.1016/j.canrad.2019.07.117.
Texto completoOrlhac, F., O. Humbert, T. Pourcher, L. Jing, J. M. Guigonis, J. Darcourt, N. Ayache y C. Bouveyron. "Analyse statistique de données radiomiques et métabolomiques : prédiction des lésions mammaires triple-négatives". Revue d'Épidémiologie et de Santé Publique 66 (mayo de 2018): S180—S181. http://dx.doi.org/10.1016/j.respe.2018.03.307.
Texto completoAmmari, Samy, Arnaud Quillent, Mickael Elhaik, Raoul Sallé de Chou, Nathalie Lassau, Émilie Chouzenoux y Corinne Balleyguier. "Analyse automatique de caractéristiques radiomiques pour le diagnostic des tumeurs de la glande parotide". Journal of Neuroradiology 48, n.º 4 (junio de 2021): 225–26. http://dx.doi.org/10.1016/j.neurad.2021.04.025.
Texto completoOrlhac, F., C. Bouveyron, T. Pourcher, L. Jing, J. M. Guigonis, J. Darcourt, N. Ayache y O. Humbert. "Identification des cancers mammaires triple-négatifs : analyse statistique de variables radiomiques issues des images TEP et de variables métabolomiques". Médecine Nucléaire 42, n.º 3 (mayo de 2018): 169. http://dx.doi.org/10.1016/j.mednuc.2018.03.096.
Texto completoTesis sobre el tema "Analyse radiomique"
Toulmonde, Maud. "Analyse Intégrée génomique, protéomique et radiomique des Sarcomes Pléomorphes Indifférenciés : Identification et Validation de nouvelles cibles thérapeutiques". Thesis, Bordeaux, 2019. http://www.theses.fr/2019BORD0429.
Texto completoUndifferentiated Pleomorphic Sarcoma (UPS) are an heterogeneous group of poorly differentiated tumors made up ‘by default’. We hypothesized that there is a link between dedifferentiation state of UPS and immune infiltrate and that this relation relies on specific pathways activation and related genomics alterations with potential therapeutic impact. Objectives of this work were to generate a comprehensive Omics landscape of UPS, integrating genomic, immuno-phenotypic, proteomic and radiomic approach, and to identify and test potential targets for therapeutic approach on cell lines and patients tumor mouse xenografts (PDX). We analyzed a cohort of 135 UPS samples from patients in our institution, of whom 25 were selected for full exome and RNA-sequencing. Unsupervised consensus and hierarchical clustering of RNA-sequencing identified 3 groups, A, B and C. Group A was mainly enriched in genes that play a crucial role in both normal development and stemcellness, notably LHX8, LRRN1, LGR5, BMP5 and FGFR2. Group B was strongly enriched in genes involved in immunity, including MARCO, TIMD4, TIGIT, CD27, IFNG, CD8B, PDCD1, CD3D and IDO1, but also DKK1. Group C was too small to be analyzed with sufficient robustness. This classification was confirmed on an independent cohort of 41 UPS from TCGA consortium. We found a high correlation between gene expression and protein density by IHC on related tumor sample slides for CD8, PD-1 and IDO1, leading to call group B ‘immune-high’ and group A ‘immune-low’. In an independent validation cohort of 110 UPS patients, CD8 expression was significantly associated with metastase-free survival (p = 0.04). Copy numbers variations were significantly more frequent in the immune-low group. Main recurrent events were deletions, notably in PTEN, RB1, FANCA, FAS, CDKN2A, TP53, AXIN1, NF2 and BRCA2. Proteomic analysis allowed us to detect two main proteomic groups - PA and PB – that highly correlated with the two main transcriptomic groups - A and B. Group PB was significantly enriched in immune response pathways, whereas group PA was enriched in MYC targets and epithelial-mesenchymal transition pathways. We then further developed cell lines and PDX models from patient tumor samples included in the molecular profiling study for each class, A, B, C. We showed robust in vitro and in vivo anti-tumor activity of FGFR inhibitor JNJ-42756493 in cell lines and PDX models from group A, selectively. We also showed in vitro activity of three potent dual inhibitors of BET-proteins CBP/P300, CPI637, NEO1132 and NEO2734, in cell lines from group A, selectively. Finally, we showed that a set of 9 radiomic features from basic MRI conventional sequences correlated well with our UPS molecular classification and provided the basis for a radiomics signature that could select immune-high UPS on their pretherapeutic imaging. This study is the first to give a comprehensive genomic, immuno-phenotypic, proteomic and radiomic landscape of non-pretreated primary UPS. We identified two main groups of UPS with therapeutics potential: the immunehigh group, strongly inflamed and probably the best candidate for immunotherapy, and the immune-low group, with a rational for FGFR and BET inhibitors activity in this one
Ahrari, Shamimeh. "Implémentation de la radiomique en routine clinique : approche individuelle et analyse de la composante temporelle par des approches d’apprentissage automatique en TEP pour la neuro-oncologie". Electronic Thesis or Diss., Université de Lorraine, 2024. https://docnum.univ-lorraine.fr/public/DDOC_T_2024_0092_AHRARI.pdf.
Texto completoWith the growing emphasis on personalized medicine, a non-invasive glioma characterization tool is essential, aiding clinicians in making optimal decisions to improve patient survival while preserving their quality of life. Medical imaging techniques such as Magnetic Resonance Imaging (MRI) and Positron Emission Tomography (PET) offer a promising solution in neuro-oncology for the non-invasive diagnosis and monitoring of gliomas. In this context, PET molecular imaging, particularly with amino acid radiotracers such as 18F-FDOPA, is currently recommended by international guidelines as an adjunct to conventional MRI. Advancements in image processing are now focused on quantifying tumor heterogeneity through the massive extraction of characteristics, known as radiomics analysis. However, this analysis has primarily been applied to static images acquired at a fixed time, ignoring the temporal dimension. In contrast, dynamic analysis offers a unique perspective by capturing the temporal variations of tumor metabolism, providing complementary information to static analysis. While region-based dynamic parameters have shown promising results for the initial diagnosis, they have limitations in detecting glioma recurrences. This thesis therefore explores the potential of machine learning-based radiomics analysis on dynamic PET acquisition at the voxel level to identify biomarkers of interest for glioma cancer indications. The temporal dimension of radiomics analysis can be addressed on two levels: by tracking the kinetics of tumor metabolism through single-time-point dynamic acquisition, and by monitoring changes in patient status over multiple examinations. Initially, this work investigated the impact of point spread function deconvolution, a common post-reconstruction technique at our institution, on voxel-based dynamic analysis. Subsequently, the first aspect of the temporal dimension was evaluated through radiomics analysis of single-time-point dynamic PET images at the voxel level. The prognostic value of this analysis for glioma recurrence detection was modest. Therefore, the temporal dimension of radiomics analysis was further explored by examining changes in radiomics features between two consecutive PET scans, aiming to monitor the post-treatment status of patients with glioma. A multicenter validation study was then conducted to assess the potential of integrating radiomics analysis into clinical practice. The objective was to investigate the impact of an explainable radiomics model on the diagnostic performance of physicians in determining the aggressiveness of suspected gliomas at the initial diagnosis. To go further, the feasibility of adapting deep learning algorithms to the analysis of 18F-FDOPA PET imaging is encouraging. This approach could provide greater flexibility in model explainability while capturing the complex relationships between PET imaging features and patient outcomes
Khalid, Fahad. "Magnetic Resonance Imaging and Genomic Mutation in Diffuse Intrinsic Pontine Glioma : Machine Learning Approaches for a Comprehensive Analysis". Electronic Thesis or Diss., université Paris-Saclay, 2024. http://www.theses.fr/2024UPAST006.
Texto completoThe diagnosis of diffuse intrinsic pontine glioma (DIPG) in children stands as one of the most harrowing within pediatric oncology. Despite numerous clinical trials exploring various treatments, the prognosis remains bleak, with most patients succumbing between 9 to 11 months post-diagnosis. Key gene mutations linked to DIPG include H3K27M, ACVR1, and TP53. Each mutation has distinct characteristics, leading physicians to suggest tailored therapies, underscoring the importance of accurate mutation detection in guiding treatment. Located in the crucial region of the brainstem, the pons, DIPG tumors pose significant biopsy risks due to potential neurological damage. Hence, MRI could become a primordial diagnostic tool for these tumors, assessing their spread and gauging therapy responses. Its use to predict accurate gene mutation, and identify long-term survivors, could enhance patient care significantly. Within this framework, radiomics transforms images into vast data sources, extracting features like shape and texture to aid decision-making. The objective of this thesis is to refine mutation prediction and pinpoint long-term survivors, emphasizing image normalization and the applicability of radiomic models. Our study utilized a retrospective database from Gustave Roussy Institute, encompassing 80 patients MRI data and their respective clinical data. These MRI images highlighted issues in radiomic studies, such as bias field inhomogeneity and the "scanner effect". To address these challenges, a dedicated MR image normalization pipeline was implemented, and radiomic features underwent ComBat harmonization. Given the dataset's missing modalities, a multi-model strategy was employed, leading to 16 distinct models based on various radiomic and clinical feature combinations. This approach was then streamlined into a multi-modal method, reducing the number of models to five. The results from the ensemble of these models proved to be the most promising. This multi-modal strategy incorporated a feature selection phase, pinpointing the most pertinent features. Additionally, this method was applied to identify long-term survivors and was complemented by the ICARE framework for a nuanced survival analysis output
Perier, Cynthia. "Analyse quantitative des données de routine clinique pour le pronostic précoce en oncologie". Thesis, Bordeaux, 2019. http://www.theses.fr/2019BORD0219/document.
Texto completoTumor shape and texture evolution may highlight internal modifications resulting from the progression of cancer. In this work, we want to study the contribution of delta-radiomics features to cancer-evolution prediction. Our goal is to provide a complete pipeline from the 3D reconstruction of the volume of interest to the prediction of its evolution, using routinely acquired data only.To this end, we first analyse a subset of MRI(-extracted) radiomics biomarquers in order to determine conditions that ensure their robustness. Then, we determine the prerequisites of features reliability and explore the impact of both reconstruction and image processing (rescaling, grey-level normalization). A first clinical study emphasizes some statistically-relevant MRI radiomics features associated with event-free survival in anal carcinoma.We then develop machine-learning models to improve our results.Radiomics and machine learning approaches were then combined in a study on high grade soft tissu sarcoma (STS). Combining Radiomics and machine-learning approaches in a study on high-grade soft tissue sarcoma, we find out that a T2-MRI delta-radiomic signature with only three features is enough to construct a classifier able to predict the STS histological response to neoadjuvant chemotherapy. Our ML pipeline is then trained and tested on a middle-size clinical dataset in order to predict early metastatic relapse of patients with breast cancer. This classification model is then compared to the relapsing time predicted by the mechanistic model.Finally we discuss the contribution of deep-learning techniques to extend our pipeline with tumor automatic segmentation or edema detection
Reuzé, Sylvain. "Extraction et analyse de biomarqueurs issus des imageries TEP et IRM pour l'amélioration de la planification de traitement en radiothérapie". Thesis, Université Paris-Saclay (ComUE), 2018. http://www.theses.fr/2018SACLS341/document.
Texto completoBeyond the conventional techniques of diagnosis and follow-up of cancer, radiomic analysis allows to personalize radiotherapy treatments, by proposing a non-invasive characterization of tumor heterogeneity. Based on the extraction of advanced quantitative parameters (histograms of intensities, texture, shape) from multimodal imaging, this technique has notably proved its interest in determining predictive signatures of treatment response. During this thesis, signatures of cervical cancer recurrence have been developed, based on radiomic analysis alone or in combination with conventional biomarkers, providing major perspectives in the stratification of patients that can lead to dosimetric treatment plan adaptation.However, various methodological barriers were raised, notably related to the great variability of the protocols and technologies of image acquisition, which leads to major biases in multicentric radiomic studies. These biases were assessed using phantom acquisitions and multicenter patient images for PET imaging, and two methods enabling a correction of the stratification effect were proposed. In MRI, a method of standardization of images by harmonization of histograms has been evaluated in brain tumors.To go further in the characterization of intra-tumor heterogeneity and to allow the implementation of a personalized radiotherapy, a method for local texture analysis has been developed. Specifically adapted to brain MRI, its ability to differentiate sub-regions of radionecrosis or tumor recurrence was evaluated. For this purpose, parametric heterogeneity maps have been proposed to experts as additional MRI sequences.In the future, validation of the predictive models in external centers, as well as the establishment of clinical trials integrating these methods to personalize radiotherapy treatments, will be mandatory steps for the integration of radiomic in the clinical routine
Jaouen, Tristan. "Caractérisation du cancer de la prostate de haut grade à l’IRM multiparamétrique à l’aide d’un système de diagnostic assisté par ordinateur basé sur la radiomique et utilisé comme lecteur autonome ou comme second lecteur". Electronic Thesis or Diss., Lyon, 2022. http://www.theses.fr/2022LYSE1140.
Texto completoWe developed a region of interest-based (ROIs) computer-aided diagnosis system (CAD) to characterize International Society of Urological Pathology grade (ISUP) ≥2 prostate cancers at multiparametric MRI (mp-MRI). Image parameters from two multi-vendor datasets of 265 pre-prostatectomy and 112 pre-biopsy MRIs were combined using logistic regression. The best models used the ADC 2nd percentile (ADC2) and normalized wash-in rate (WI) in the peripheral zone (PZ) and the ADC 25th percentile (ADC25) in the transition zone (TZ). They were combined in the CAD system. The CAD was retrospectively assessed on two multi-vendor datasets containing respectively 158 and 105 pre-biopsy MRIs from our institution (internal test dataset) and another institution (external test dataset). Two radiologists independently outlined lesions targeted at biopsy. The Prostate Imaging-Reporting and Data System version 2 (PI-RADSv2) score prospectively assigned at biopsy and the CAD score were compared to biopsy findings. At patient level, the areas under the Receiver Operating Characteristic curve (AUC) of the PI-RADSv2 score were 82% (95% CI: 74-87) and 85% (95% CI: 79-91) in the internal and external test datasets respectively. For both radiologists, the CAD score had similar AUC results in the internal (82%, 95% CI: 76-89, p=1; 84%, 95% CI: 78-91, p=1) and external (82%, 95% CI: 76-89, p=0.82; 86%, 95% CI: 79-93, p=1) test datasets. Combining PI-RADSv2 and CAD findings could have avoided 41-52% of biopsies while missing 6-10% of ISUP≥2 cancers. The CAD system confirmed its robustness showing good discrimination of ISUP ≥2 cancers in a multicentric study involving 22 different scanners with highly heterogeneous image protocols. In per patient analysis, the CAD and the PI-RADSv2 had similar AUC values (76%, 95% CI: 70-82 vs 79%, 95% CI: 73-86; p=0.34) and sensitivities (86%, 95% CI: 76-96 vs 89%, 95% CI: 79-98 for PI-RADSv2 ≥4). The specificity of the CAD (62%, 95% CI: 53-70 vs 49%, 95% CI: 39-59 for PI-RADSv2 ≥4) could be used to complement the PI-RADSv2 score and potentially avoid 50% of biopsies, while missing 13% of ISUP ≥2 cancers. These findings were very similar to those reported in the single center test cohorts. Given its robustness, the CAD could then be exploited in more specific applications. The CAD first provided good discrimination of ISUP ≥2 cancers in patients under Active Surveillance. Its AUC (80%, 95% CI: 74-86) was similar to that of the PI-RADS score prospectively assigned by specialized uro-radiologists at the time of biopsy (81%, 95% CI: 74-87; p=0.96). After dichotomization, the CAD was more specific than the PI-RADS ≥3 (p<0.001) and the PI-RADS ≥4 scores (p<0.001). It could offer a solution to select patients who could safely avoid confirmatory or follow-up biopsy during Active Surveillance (25%), while missing 5% of ISUP≥2 cancers. Finally, the CAD was tested with the pre-prostatectomy mp-MRIs of 56 Japanese patients, from a population which is geographically distant from its training population and which is of interest because of its low prostate cancer incidence and mortality. The CAD obtained an AUC similar to the PI-RADSv2 score assigned by an experience radiologist in the PZ (80%, 95% CI: 71-90 vs 80%, 95% CI: 71-89; p=0.886) and in the TZ (79%, 95% CI: 66-90 vs 93%, 95%CI: 82-96; p=0.051). These promising and robust results across heterogeneous datasets suggest that the CAD could be used in clinical routine as a second opinion reader to help select the patients who could safely avoid biopsy. This CAD may assist less experience readers in the characterization of prostate lesions
Boughdad, Sarah. "Contributions of radiomics in ¹⁸F-FDG PET/CT and in MRI in breast cancer". Thesis, Université Paris-Saclay (ComUE), 2018. http://www.theses.fr/2018SACLS500.
Texto completoBreast cancer is a common disease for which ¹⁸F-FDG PET/CT and breast MRI are frequently performed in routine practice. However, the different information provided by each of these imaging techniques are currently under-exploited. Indeed, in routine the interpretation of these scans is mainly based on visual analysis whereas the « quantitative » analysis of PET/CT data is generally limited to the sole use of the SUVmax while in breast MRI, simple parameters to characterize tumor enhancement after injection of contrast medium are used. The advent of PET/MRI machines, calls for an evaluation of the contribution of a more advanced quantification of each of the modalities separately and in combination in the setting of breast cancer. This is along with the concept of « Radiomics » a field currently expanding and which consists in extracting many quantitative characteristics from medical images used in clinical practice to decipher tumor heterogeneity or improve prediction of prognosis. The aim of our work was to study the contribution of radiomic data extracted from ¹⁸F-FDG PET and MRI imaging with contrast injection to characterize tumor heterogeneity in breast cancer taking into account the different molecular subtypes of breast cancer, namely luminal (Lum A, Lum B HER2- and Lum B HER2 +), triple-negative and HER2 + tumors. In this context, we focused on the prediction of prognosis in patients treated with neo-adjuvant chemotherapy. The influence of physiological variations such as age on the calculation of radiomic data in normal breast and breast tumors separately was also explored, as well as the multi-center variability of radioman features. Radiomic features were extracted using the LiFex software developed within IMIV laboratory. The patient database used for the studies were all retrospective data. We reported for the first time the influence of age on the values of radiomic features in healthy breast tissue in patients recruited from 2 different institutions but also in breast tumors especially those with a triple-negative subtype. Similarly, significant associations between the radiomic tumor phenotype in PET and MRI imaging and well-established prognostic factors in breast cancer have been identified. In addition, we showed a large variability in the PET « radiomic profile » of breast tumors with similar breast cancer subtype suggesting complementary information within their metabolic phenotype defined by radiomic features. Moreover, taking into account this variability has been shown to be of particular interest in improving the prediction of pathological response in patients with triple-negative tumors treated with neoadjuvant chemotherapy. A peri-tumoral breast tissue region satellite to the breast tumor was also investigated and appeared to bear some prognostic information in patients with Lum B HER2- tumors treated with neoadjuvant chemotherapy. In MR, we demonstrated the need to harmonize the methods for radiomic feature calculation. Overall, we observed that radiomic features derived from MR were less informative about the molecular features of the tumors than radiomic features extracted from PET data and were of lower prognostic value. Yet, the combination of the enhanced tumor volume in MR with a PET radiomic feature and the tumor molecular subtype yielded enhanced the accuracy with which response to neoadjuvant therapy could be predicted compared to features from one modality only or molecular subtype only